Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Bull Cancer. 2024 Apr 16:S0007-4551(24)00119-X. doi: 10.1016/j.bulcan.2024.02.013. Online ahead of print.ABSTRACTChimeric antigen receptor T cell (CAR-T cell) therapy has become a standard-of-care for several hematological and a promising treatment for solid malignancies or for selected non-malignant autoimmune disorders. Hematological complications following this treatment are very common with the majority of patients experiencing at least one cytopenia after CAR-T cell injections. The management of these adverse events is not standardized and represents an area of active research and unmet clinical needs. This harmonization workshop, gathering a group of experts who analyzed this topic, has been conceived for the optimization of the management of patients presenting with post-CAR-T cell hematological toxicities. Based on the data present in the literature, these practical recommendations were made to harmonize the practices of Francophone centers involved in the management of these patients.PMID:38631984 | DOI:10.1016/j.bulcan.2024.02.013
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research